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Background: Since the introduction of endovascular repair (EVR) for infrarenal abdominal aortic aneurysm (AAA),
clinical evaluation has been under way in many countries throughout the world. The main purpose of this retrospective
study was to determine outcome of EVR with aortic endovascular prostheses (AEPs) and to evaluate the extent to which
French practitioners have complied with regulatory and clinical guidelines for the use of these trial devices.
Methods: This retrospective study was conducted by the French National Health Insurance Fund for Salaried Workers.
Data were compiled on EVR procedures performed at health care institutions all over mainland France between June
1999 and May 2001.
Results: A total of 1012 AEPs were deployed for AAA repair in France during the study period. Only 151 (14.9%) of these
EVR procedures were carried out within an approved investigational setting with informed patient consent. Only 149 of
the 861 patients (17.3%, 95% confidence interval [CI], 14.9 to 19.9%) who underwent endovascular repair in
noninvestigational settings signed informed consent forms. In 452 cases (46.5%), the diameter of the AAA was 50 mm
or less. Complete outcome data for the first year were available for 891 patients (88%). Complications occurred in 177 of
these patients (19.9%, 95% CI, 17.3 to 22.6%). There were a total of 47 deaths (5.3%, 95% CI, 3.9 to 6.9%), including 27
during the first 30 postoperative days. Other major events during the first year after AEP implantation were ruptured
AAA in 5 patients, conversion to open operation in 15, and additional endovascular treatment in 52. Data on clinical
surveillance were available for 987 patients (97.5%) with a mean follow-up of 345 days. Only 294 patients (29.8%, 95%
CI, 27.0 to 32.7%) underwent complete imaging within the first month after AEP implantation. A total of 184 patients
(18.6%, 95% CI, 16.3 to 21.2%) received no surveillance at all.
Conclusion: This study shows the need for improvement in the clinical evaluation of new devices and medical technologies
in France. Study findings also confirm the significant incidence of adverse outcomes and necessity for routine surveillance
after EVR of AAA with AEP. However, risk/benefit analysis is difficult because most procedures were not carried out
within a proper investigational context. (J Vasc Surg 2003;38:1273-82.)
Abdominal aortic aneurysm (AAA) is a life-threatening
condition predominantly affecting men over 60 years of
age. The overall prevalence of AAA larger than 45 mm in
men older than 50 years is estimated to be 6%, and a
number of studies1-4 suggest that incidence is increasing.
The overall mortality rate for ruptured AAA is about 80%,
and only about half of the patients who undergo emergency
operation will survive.2,5 As increasing aneurysm diameter
is a major predictor of rupture, the current therapeutic
approach to AAA calls for surveillance or repair according
to diameter. According to guidelines published in 1999 by
the French Agency for Accreditation and Evaluation in
Health (ANAES, French acronym)6 and in 2001 by the
French Agency for Sanitary Safety of Health Products
(AFSSAPS, French acronym),7 the critical diameter for
repair is 50 mm. However, recent randomized studies8,9
have shown no significant difference in mortality between
patients receiving regular ultrasound scanning follow-up
and those receiving immediate treatment for aneurysms
between 40 and 55 mm in diameter.
For more than 40 years, surgery was the only available
method of repair for AAA. In the literature, mean postop-
erative mortality for elective surgery has been less than 5%10
and morbidity was 13% in a cohort of 1135 consecutive
patients.11 The long-term outcome of open surgical repair
(OSR) of AAA is excellent. The incidence of late graft
complications has been low, ranging from 4% at 38
months11 to 7% at 5 years.12
In 1991, Parodi et al13 described the first endovascular
repair (EVR) of AAA with an aortic endovascular prosthesis
(AEP) for AAA. The primary goal of this approach is
exclusion of the aneurysm from the circulation in the hope
that the risk of subsequent rupture will be significantly
reduced. The main benefits of EVR versus OSR are a
shorter hospital stay, lower morbidity, and quicker recov-
ery.14
Since the first successful minimally invasive procedure
was reported, a great interest in EVR has developed
throughout the world. Manufacturers began intense re-
search and development programs to design stent grafts.
Practitioners began to place more and more of these devices
for treatment of aortic and peripheral vascular aneurysms.
According to the voluntary registry of the French Society of
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Vascular Surgery (SCV, French acronym), a total of 944
AEPs were inserted in France between 1991 and 1999: 841
for infrarenal aortic aneurysm and 103 for thoracic aortic
aneurysm. These figures are probably underestimations
because they correspond to responses from only 262 of the
389 French SCV members (67.3%) invited to participate in
the SCV registry.
As elsewhere, preliminary experience in France has
shown that EVR is not devoid of morbidity and risks. Many
initial problems were caused by device-related defects in-
volving graft materials, attachment systems, and delivery
systems.15 Another early lesson was the need for careful
patient selection based on the morphologic features be-
cause insufficient neck length, excessive tortuosity, inade-
quate femoral or iliac access, and severe calcification can
prevent deployment.16 Preliminary experience also showed
that EVR not only shared some of the same potential
adverse outcomes as OSR but also added a few of its own.
The main EVR-specific problem is development of type I
and type II endoleaks involving pressurized blood flow into
the aneurysmal sac that can lead to aneurysm growth and
rupture.14,15,17 Mainly because of concerns about the
long-term reliability of endovascular repair, in March 1999,
the ANAES in France published a regulatory document6
stating that EVR for AAA was not an approved technique
and providing clear guidelines for the use of AEPs (Table
I). As a consequence, EVR was subject to the Huriet Act
(Law 88-1138 of December 1988) protecting the rights of
individuals participating in biomedical research.6 The two
major requirements of the Huriet Act involve informed
consent from patients and payment of trial costs by the trial
initiator.
Despite these guidelines, the AFSSAPS reported severe
incidents in France involving the use of AEPs in April 1999
and December 2000 and re-emphasized the requirement
that patients undergoing EVR were subject to ANAES
constraints (Table I). In compliance with European Direc-
tive 93/42 EEC of June 1993, the AFSSAPS also con-
ducted a thorough study to evaluate the safety of all AEPs
on the market in June 2000 and defined the conditions for
their use. On the basis of (1) preclinical in vitro and in vivo
data, (2) clinical data, (3) risk analysis, and (4) sterilization
procedures, the AFSSAPS recommended that further limi-
tations be put on EVR procedures in France in terms of
both approved devices and conditions for their use.7
In 2000, the results of limited studies by the French
National Health Insurance Fund for Salaried Workers
(CNAMTS, French acronym) suggested that some practi-
tioners at both public and private institutions in France
were not complying with the guidelines of ANAES. Con-
sequently, CNAMTS decided to undertake a comprehen-
sive retrospective survey to evaluate postoperative compli-
cations after placement of AEPs in France and the extent to
which French practitioners have complied with guidelines
of the ANAES6 for the use of these trial devices. The
purpose of this report is to describe the findings of that
study.
PATIENTS AND METHODS
Work group. This study was designed to allow impar-
tial analysis independent of administrative, commercial, or
political interests. It was conducted by a work group of
CNAMTS medical advisors under direction of the Head of
the CNAMTS Medical Service Department. CNAMTS is
Table I. ANAES recommendations concerning endovascular repair of AAA using aortic endovascular prosthesis in
France5
Factor Recommendation
Environment EVR must be performed in a center that routinely performs open surgical repair (OSR) and EVR.
Surgeons and radiologists should collaborate. To be certified for the procedure, practitioners
must have assisted 5 previous EVRs and performed 10 EVRs as first operator in the presence of
a certified expert. Operating room must be adequately equipped with digital equipment,
including contrast media injector.
Medical device In addition to carrying the CE mark, AEPs must undergo previous clinical testing with a protocol
with clear objectives and precise evaluation criteria.
Patient selection EVR should be performed in well-designed prospective clinical trials. Risk factors should be
carefully evaluated in all patients. The AAA should have accepted morphologic features for
AEP insertion as determined by imaging studies, including spiral CT scan and digital
angiography using a graduated catheter. The diameter of the AAA should be larger than 50
mm. These data should be summarized in a detailed written report, including all medical,
radiologic, surgical, and anesthetic data.
Patient information Patients should be informed of the risk of EVR and OSR for AAA. Written consent must be
obtained.
Follow-up Routine follow-up is obligatory after EVR for AAA using AEP. The practitioner who placed the
AEP is wholly responsible for follow-up during the hospitalization, including arteriographic
control, plain abdominal films (PAF) with A/P, lateral, right and left oblique 3/4 views. CT
scan with contrast media injection and PAF should be performed every 6 months after discharge.
Registry Cases involving EVR for AAA using AEP must be reported to the national registry. If the AEP is
removed, it must be sent to an independent laboratory for examination in cooperation with the
manufacturer who developed the AEP.
ANAES, French Agency for Accreditation and Evaluation in Health; EVR, endovascular repair; AAA, abdominal aortic aneurysm; AEP, aortic endovascular
prosthesis; CE, European Community; CT, computed tomography.
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the Healthcare Financing Administration that covers health
care costs for roughly 80% of the French population. All
CNAMTS medical advisors are nonpracticing physicians
responsible for overseeing medical cost reimbursements.
None of the medical advisors in the work group attended
an EVR or investigated a procedure carried out in an
institution where he or she had formerly practiced. Study
findings were presented to the surgeon, who was free to
provide any corrections or addendums that he or she
deemed necessary.
Data collection. Data were collected from the medical
files of all patients who underwent an EVR for AAA in
France from June 1, 1999 to May 31, 2001. A list of all
public and private centers performing vascular surgery or
interventional radiology or cardiology was compiled. To
ensure the validity of this list, it was checked at the regional
level on the basis of information from local CNAMTS
medical advisors, records of each center’s activities, and
requests for reimbursement of AEP by practitioners as per
internal CNAMTS memorandum 1912-1997. In addition,
the computerized patient and data tracking (PMSI, French
acronym) coding system (Diagnostic Related Groups) was
searched to identify institutions caring for patients with
aortic aneurysms. Two search requests were used. The first
was aortic aneurysm as principal diagnosis in association
with ten International Classification of Diseases codes
(171.0 to 171.9) and the so-called “surgical” Homoge-
nous Groups of Patients (GHM, French acronym) in Di-
agnosis Category (CMD) 05 (GHM 158, 159, 160, 168,
172). The second search also used aortic aneurysm as the
principal diagnosis but in association with group 880 of the
Major Category (CM 24), corresponding to immediate
death. These computer searches were designed to ensure
identification of any institution that had admitted more
than 15 AAA patients per year.
Every procedure involving insertion, reinsertion, or
ablation of an AEP was recorded on a data spreadsheet. To
ensure that no procedure was overlooked, medical advisors
met with the pharmacy and sterile medical devices commit-
tees and the head of the medical device vigilance depart-
ment to obtain a list of all reported devices and accidents.
They also consulted operating-room registers and compul-
sory registers for the procedures performed in radiology
suites.
Data analysis. Data analysis involved information
about clinical setting, patients, practitioners, clinical find-
ings, and compliance with guidelines for AEP use. Clinical
data included patient characteristics, preoperative evalua-
tion, and adverse outcomes distinguishing between those
related to “device or procedure” and other complications.
Assessment of guideline compliance involved informed
consent, research protocol, use of European Community
(CE)-marked devices, and reporting of any medical device
incident to the vigilance committee of the AFSSAPS.
Statistical analysis. Statistical analysis was performed
with Microsoft Excel (Microsoft Corp, Redmond, Wash)
and SPSS (SPSS Inc, Chicago, Ill) software. Variables were
cross-checked, and queries were sent to regional project
directors concerning missing or aberrant data. Any proce-
dures with a “no answer” rate higher than 25% were ex-
cluded from statistical analysis. The Pearson 2 test was
used to compare percentages for qualitative variables.
Means with calculation of 95% percent confidence (CI)
interval and standard deviation (SD) were used for the
analysis of quantitative variables.
RESULTS
Clinical setting. During the 2-year study period, a
total of 1012 AEPs were deployed in France for treatment
of AAA, including 930 procedures (92%) at 46 public
centers and 62 procedures (8%) at 19 private institutions.
Table II shows the distribution of these procedures accord-
ing to region and type of facility. Three regions—Ile-de-
France, Provence-Alpes-Coˇte-d’Azur, and Rhoˇne-Alpes,—
accounted for 60% of procedures (n  614). The number
of AEPs inserted for EVR of AAA was 1 at 9 centers (14%),
2 to 10 at 37 centers (57%), 11 to 50 at 23 centers (35%),
51 to 100 at 2 centers (5%), and over 100 (3%) at 2 centers.
It was difficult to determine how many devices had been
inserted by each practitioner, for several reasons. Many
procedures were performed by two physicians working
together. Some practitioners had operating privileges in
several institutions, both public and private, or were often
involved in teaching. Furthermore, this study was not de-
signed to assess the training of the practitioners.
Patient characteristics. Most patients (93.6%; n 
947) were men. As shown in Table III, mean patient age
was 72  9 years (range, 33 to 99 years). The patient was
older than 70 years in 642 cases (63.4%). On the basis of
associated risk factors mentioned in the medical records, it
was possible to classify 853 patients (84%) according to the
American Society of Anesthesiologists (ASA) system (Table
IV). There were 313 patients (36.7%) in ASA I or II, 438
(51.3%) in ASA III, and 102 (11.2%) in ASA IV or V.
According to medical records, patients in ASA IV or V were
treated out of “compassion.” The overall mean duration of
hospital stay was 9  8 days, with a median of 8 days.
Preoperative evaluation. All patients underwent im-
aging for morphologic assessment of their AAA, including
spiral computed tomography (CT) scans in 913 out of 986
cases (92.6%) and digitized angiography with placement of
a graduated catheter in the aneurysm in 909 out of 975
cases (93.2%). Angiography was performed more often in
the public (855/903) than in the private (54/72) sector (P
 .001; odds ratio [OR] 5.9; 95% CI, 3.2 to 10.9).
Discussion of the indication for EVR in a radiology–vascu-
lar surgery staff meeting was documented in only 227 cases
(22.7%).
The location of the aneurysm was clearly defined in the
patient’s medical file in 956 cases (94%). The neck of the
aneurysm was infrarenal with moderate iliac dilation in 948
cases (93.7%). Infrarenal AAA was associated with common
iliac aneurysms ranging in diameter from 25 to 30 mm in
eight patients (0.8%). The exact location of the AAA could
not be determined from the patient’s medical file in 56
cases (6%).
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Maximum AAA diameter was specified in the patient’s
medical record in 904 cases (89.4%). As shown in Table V,
280 AAAs (31%) had a diameter less than 50 mm. All of
these patients were symptom-free except four, who com-
plained of abdominal pain. In four patients, the aneurysm
had expanded by 10 mm or more over a 12-month period.
The diameter of the aneurysm was reported to be exactly 50
mm in 145 cases (16.0%). The remaining 479 patients
(53.0%) had aneurysms larger than 50 mm.
Type of procedure and devices. The type of the
endovascular procedure performed was clearly noted in the
patient’s medical file in 930 cases (92%). It consisted of
first-time EVR in 881 cases (95%), insertion of an addi-
tional AEP in 34 cases (3.6%), and ablation of an AEP with
conversion to open repair in 15 cases (1.4%). Reinterven-
tion was significantly more frequent (P  .004, OR: 3.7,
95% CI: 1.6 to 8.6) in private (8/82) than in public
institutions (26/930).
Bifurcated stent grafts were used in 74.8% of cases,
aortouniiliac stent grafts in 15.6%, and aortoaortic stent
grafts in 9.6%. Table VI shows the different AEP models
used. Ten different devices were employed, including nine
stent grafts manufactured by different companies and one
made-to-measure stent graft. Only one of the commercially
available devices used in this study had not received CE
approval—the Vanguard III system (Boston Scientific,
Natick, Mass), which was used seven times in an unap-
proved clinical trial at the same institution. Custom-made
stent grafts constructed by the surgeons accounted for
12.3% of all the endovascular prostheses inserted. These
devices, consisting of Z auto-expandable stainless steel
stents connected with commercially available polyester vas-
Table II. Number of abdominal aortic prostheses used in each region of mainland France for endovascular repairs for
abdominal aortic aneurysm with aortic endovascular prostheses performed in public and private institutions from June 1,
1999 to May 31, 2001
Region
Public institutions Private institutions Total
Patients % Patients % Patients %
Alsace 3 0.3 0 0 3 0.3
Aquitaine 14 1.5 0 0 14 1.4
Auvergne 5 0.5 0 0 5 0.5
Basse-Normandie 6 0.6 0 0 6 0.6
Bourgogne 24 2.6 0 0 24 2.4
Bretagne 34 3.7 0 0 34 3.4
Centre 10 1.1 0 0 10 1.0
Champagne-Ardenne 22 2.4 4 4.9 26 2.6
Franche-Comte´ 1 0.1 2 2.4 3 0.3
Haute-Normandie 9 1.0 0 0 9 0.9
Ile-de-France 281 30.2 26 31.7 307 30.3
Languedoc-Roussillon 19 2.0 0 0 19 1.9
Limousin 1 0.1 0 0 1 0.1
Lorraine 6 0.6 6 7.3 12 1.2
Midi-Pyre´ne´es 32 3.4 11 13.4 43 4.2
Nord-Pas-de-Calais 77 8.3 14 17.1 91 9.0
PACA 155 16.7 15 18.3 170 16.8
Pays-de-la-Loire 53 5.7 0 0 53 5.2
Picardie 29 3.1 0 0 29 2.9
Poitou-Charentes 15 1.6 1 1.2 16 1.6
Rhoˆne-Alpes 134 14.4 3 3.7 137 13.5
Total in mainland France 930 100 82 100 1012 100
PACA, Re´gion Provence-Alpes-Coˆte d’Azur.
Table III. Age distribution of patients who underwent endovascular repair for abdominal aortic aneurysm using aortic
endovascular prostheses in public and private institutions in mainland France from June 1, 1999 to May 31, 2001.
There was no significant difference between public and private institutions concerning patient’s age (P  .07)
Age
Public institutions Private institutions Total
Patients % Patients % Patients %
Less than 50 years 14 1.5 2 2.4 16 1.6
50 to 59 years 71 7.6 4 4.9 75 7.4
60 to 69 years 265 28.5 14 17.1 279 27.6
Over 69 years 580 62.4 62 75.6 642 63.4
Total 930 100.0 82 100.0 1012 100.0
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cular grafts, were sterilized the day before surgery and
loaded into the introducer during the implantation proce-
dure.18
Various additional procedures were performed in asso-
ciation with AEP insertion. Iliac or femoral bypass, iliac or
femoral endarterectomy, or another vascular intervention
was performed in 285 patients (28.2%). Additional proce-
dures were not considered to be complication-related un-
less specifically designated as such in the patient’s medical
file.
Surveillance of the aortic endovascular prostheses.
Immediate and 1-year follow-up data (mean duration, 345
 230 days) were available in the medical records of 987
patients (97.5%; 95% CI, 96.3 to 98.3%) and demonstrated
poor compliance with recommendations issued by the AN-
AES6 on follow-up after EVR with AEP. These recommen-
Table IV. Distribution according to ASA score of patients who underwent endovascular repair for abdominal aortic
aneurysm with aortic endovascular prostheses in public and private institutions in mainland France from June 1, 1999 to
May 31, 2001.
ASA Scores
Public institutions Private institutions Total
Patients % Patients % Patients %
ASA 1 20 2.5 5 7.8 25 2.9
ASA 2 270 34.2 18 28.1 288 33.8
ASA 3 399 50.7 39 60.9 438 51.4
ASA 4–5 100 12.6 2 3.2 102 11.9
Total 789 100.0 64 100.0 853 100.0
ASA score could be determined in 853 of the 1012 patients included in study (84%). There was no significant difference between public and private institutions
concerning ASA score.
ASA, American Society of Anesthesiologists.
Table V. Distribution according to maximum aneurysm diameter of patients who underwent endovascular repair for
abdominal aortic aneurysm using aortic endovascular prostheses in public and private institutions in mainland France
from June 1, 1999 to May 31, 2001
Aneurysm diameter
Public institutions Private institutions Total
Patients % Patients % Patients %
Less than 50 mm 280 31.0 13 19.1 293 30.1
Equal to 50 mm 145 16.0 14 20.6 159 16.4
Between 50 and 70 mm 429 47.5 35 51.5 464 47.7
Equal to or greater than 70 mm 50 5.5 6 8.8 56 5.8
Total 904 100.0 68 100.0 972 100.0
Aneurysm diameter was not available in 68 Patients (10.6%). There was no significant difference between public and private institutions concerning AAA
diameter (P  0.16).
Table VI. Type of abdominal aortic endovascular prosthesis inserted in patients who underwent endovascular repair for
abdominal aortic aneurysm with aortic endovascular prostheses in public and private institutions in mainland France
from June 1, 1999 to May 31, 2001
Model
Public facility Private facility Total
No. % No. % No. %
Ancure (Guidant EVT) 20 2.2 0 0 20 2.1
AneuRx (Medtronic) 147 16.5 10 13.5 157 16.3
Gad (Baxter) 3 0.3 0 0 3 0.3
Excluder (Gore) 97 10.9 0 0 97 10.1
Powerlink System (Endologix) 145 16.3 13 17.6 158 16.4
Stenford (Stenford) 4 0.4 13 17.6 17 1.8
Talent (Medtronic) 175 19.7 22 29.7 197 20.4
Vanguard (Boston) 46 5.2 11 14.9 57 5.9
Zenith (Cook) 134 15.1 5 6.8 139 14.4
Custom-made by surgeons 119 13.4 0 0 119 12.3
Total 890 100.0 74 100.0 964 100.0
The type of AEP was not stated in the medical file of 48 patients (4.7%).
EVR, Endovascular repair.
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dations are similar to those issued by the Food and Drug
Administration for investigations involving cardiovascular
devices in the United States.19 Follow-up procedures car-
ried out in the hospital during the immediate recovery
period included discharge angiography in 894 patients
(91%), CT scan with contrast media in 726 patients (74%),
and plain abdominal radiograph views in 724 patients
(73%). Only 385 patients (39%) underwent complete im-
aging studies as recommended by the regulatory authorities
and described in Table I. Follow-up surveillance proce-
dures carried out during the first 6 months after the proce-
dure included duplex scan in 513 patients (52%) and CT
scan with contrast media in 529 patients (53,6%). Only 294
patients (30%) underwent complete imaging studies as
recommended by the ANAES.6 Although some patients
living far from the primary treatment center may have
undergone follow-up surveillance at outside centers, study
data indicate that 184 patients (18.6%) underwent no
surveillance.
Complications. Complications were clearly described
in the patient’s medical file in 891 cases (88%). As shown in
Table VII, complications occurred during the first 30 post-
operative days in 122 patients (13.7%, 95% CI: 11.6 to
16.1%), including 27 deaths (3.1%, 95% CI: 2 to 4.4%). At
the end of 1 year (Table VII), including the first 30 post-
operative days, complications had occurred in a total of 177
patients (19.9%, 95% CI, 17.4 to 22.7%) with 47 deaths
(5.3%), including 20 (2.2%) device- or procedure-related
deaths. Complications were directly related to the proce-
dure or to the device in 15.3% and unrelated in 4.6%. A
total of 142 endoleaks were reported. Treatment for en-
doleak included conversion to open operation in 15 cases,
endovascular re-intervention to insert a new endovascular
prosthesis in 22, and embolization in 30 (Tables VII and
VIII). Additional treatment for endoleak was either not
performed (69 cases) or not specified (6 cases).
Compliance with guidelines for EVR with AEP. As
mentioned above, the 1999 ANAES guidelines (Table I)
required that all EVRs with AEP be carried out within a
clinical trial setting with written informed consent. Data
compiled in this study showed that only 151 patients
(14.9%, 95% CI: 12.8 to 17.2%) were included in a clinical
research protocol. Of the remaining 861 patients treated
outside investigational settings, only 149 (17.3%) signed
informed consent forms.
The CNAMTS medical advisors also analyzed compli-
ance with technical and medical aspects of the ANAES
guidelines (Table I). The results demonstrated that 896
(93.2%) AEPs were inserted in a facility having at least one
interventional radiologist and one vascular surgeon on staff.
In addition, 946 (94.4%) of the procedures were performed
in an operating or procedure room complying with ANAES
guidelines.
For the 1012 patients studied, only six device vigilance
reports were sent to the AFSSAPS. These reports ac-
counted for only 4.4% of 136 “device or procedure” com-
plications and 30% of 20 deaths related to “device or
procedure.”
DISCUSSION
Since the first successful EVR in 1991,13 an increasing
number of AEPs have been used for treatment of AAA in
France and elsewhere. This exhaustive study based on data
collected by thorough study of each patient’s file by
CNAMTS medical advisors provides important insight not
only into the outcome of EVR with AEPs for management
of AAA but also into the way that these devices are currently
being used and evaluated in France.
This study provided interesting data on various out-
comes of EVR, including mean hospital stay, 30-day mor-
tality, and 1-year procedure- or device-related complica-
tions and deaths. The mean duration of hospitalization for
EVR in this survey was 9 days. The shortest mean hospital
stays for EVR in France were 6  2.5 days in the study of
Becquemin et al20 and 7.8 2.3 days in the study of Ricco
et al.21 The mean duration of hospitalization for OSR of
Table VII. Complications occurring during the first 30 postoperative days after endovascular repair for abdominal aortic
aneurysm (AAA) using aortic endovascular prostheses (AEPs) in mainland France from June 1, 1999 to May 31, 2001
Complications Specific* General Deaths
Rupture of AAA 2 — 1
Endoleak or migration of AEPs surgical conversion 11 — 0
Endoleak or migration of AEPs endovascular treatment 25 — 0
Acute kidney failure - Renal artery thrombosis 11 — 5
Acute ischemia of lower limbs 16 — 4
Colon ischemia with necrosis 3 — 2
Infection 10 — 1
False femoral aneurysm 19 — 0
Multi-organ failure — 6 4
Acute respiratory failure — 6 3
Stroke — 5 3
Myocardial infarction — 8 4
Total 97 (10.9%) 25 (2.8%) 27 (3.1%)
*Specific means that the complication was related to the device or procedure.
Postoperative complications (30 postoperative days) occurred in 122 (13.7%) of the 891 patients for whom this information was available in the medical file.
There were 27 deaths (3.1%), including 13 (1.5%) that were procedure or device related and 14 (1.6%) that were caused by other causes.
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AAA in France was 12 5 days according to PMSI data and
12  2.3 days according to a multicenter study published
by Kieffer et al in 1990.22 Thus, this study appears to
confirm that mean duration of hospitalization after EVR is
shorter than after OSR. However, it should be noted that
hospitalization after both EVR and OSR are longer in
France than in North America.11,22
Analysis of this study indicated that the 30-day mortal-
ity rate after EVR was 3.1%. Although underestimation
cannot be ruled out because postoperative information was
missing in 178 medical records (18%), this rate is compa-
rable with rates reported after EVR in the Eurostar registry
(3.2%).14 In multicenter studies on OSR, mortality rates
have ranged from 2.7% to 4.9%. It was 2.7% in Lederle’s
randomized study9 and 4.9% in France.22,24 Preliminary
findings from the Lifeline registry indicate that the 1-year
mortality rate of 14.9% for EVR is comparable with that of
OSR (12.6%) in a comparable group.25 In our study, the
1-year complication rate after EVR was 19.9%. This seems
high but comparison with OSR10 is difficult because the
type and, above all, timing of complications are different
after EVR. In fact, 1-year complications after AEP insertion
may have been underestimated in this study because the
mean follow-up period was only 345 days.
The major finding of this study involves poor compli-
ance with regulatory requirements and clinical guidelines
for the use of AEPs. Four out of five AEPs were inserted
outside of an investigational setting, without informed
patient consent in 82.7% of cases. To justify their choice,
many practitioners have argued that such procedures were
licit because the devices used carried the CE-approval mark.
This argument is specious because the CE mark corre-
sponds to safety and quality standards rather than to clinical
benefit. To clarify this situation, the AFSSAP7 issued guide-
lines in 2001 specifying that only three of the eight AEPs
carrying the CE mark were approved for clinical use under
strict follow-up protocol. This study provides further evi-
dence that EVR is still experimental.
The findings of this study also indicate that French
practitioners of EVR with AEP have disregarded classic
indications for AAA repair as well as recommendations for
long-term follow-up after EVR with AEP. Fully 31% of the
AEPs used in France during the 2-year study period were
inserted in patients with AAAs measuring less than 50 mm
in diameter. According to published consensus guidelines
confirmed by two randomized studies,8,9 lesions less than
55 mm are indicated for surveillance rather than repair.
Only 294 patients (30%) underwent follow-up surveillance,
including complete imaging studies as recommended by
the ANAES,6 and 184 (18.6%) patients underwent no
follow-up surveillance. On a more positive note for most
French practitioners, compliance with guidelines concern-
ing the need to perform EVR in an operative environment
and immediate postoperative monitoring were generally
good.
Several hypotheses can be proposed to explain non-
compliance of French practitioners with legislative and
clinical requirements for EVR with AEPs. The main reason
involves the fact that penalties were initially rarely applied.
In the absence of penalties, enthusiasm for a new minimally
invasive technology and its short-term benefits may blind
many French practitioners to the still-experimental nature
of this technique and the need for caution concerning its
long-term efficacy.
Some practitioners may also have acted under pressure
from patients who had learned of EVR with AEP from the
mass public media or the Internet. However it should be
said in this regard that 3 years ago, at the time of this study,
much less medical information on the Internet was avail-
able in French than in English and that French patients
were much less inclined to use the Internet as a source of
such information than their American counterparts. In any
case, availability of information on new technology would
not have freed practitioners from their duty to inform
patients of the risks and comply with regulatory require-
ments for the use of a new medical procedure.
It is unlikely that financial interests played a major role
in practitioner’s therapeutic decision-making because most
AEPs (92%, n  930) were inserted in public hospitals
where financing comes from the global hospital endow-
Table VIII. Delayed complications occurring after the first 30 postoperative days following endovascular repair for
abdominal aortic aneurysm (AAA) using aortic endovascular prostheses (AEPs) in mainland France from June 1, 1999
to May 31, 2001.
Complications Specific* General Deaths
Rupture of AAA 3 — 2
Endoleak or migration of AEP: surgical conversion 4 — 0
Endoleak or migration of AEP: endovascular treatment 27 — 0
Renal artery thrombosis 3 — 3
Colonic ischemia with necrosis 2 — 2
Multiple organ failure — 6 6
Chronic respiratory failure — 4 4
Myocardial infarction — 6 3
Total 39 (4.4%) 16 (1.8%) 20 (2.2%)
Delayed complications occurred in 55 of the 891 patients (7.3%) for whom this information was available in the medical file. Mean follow- up for these patients
was 345  230 days. Twenty deaths (2.2%) occurred after the first postoperative month, including 7 (0.8%) that were “procedure or device” related and 13
(1.4%) that were caused by other causes.
*Specific means that the complication was related to the device or procedure.
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ment and practitioners are not paid on a per-procedure
basis. As explained in the next paragraph, the French
Healthcare Financing Administration does not provide
coverage for investigational devices, even if they are used in
accordance with the research regulation French regula-
tions. Thus, any such reimbursement for AEPs and related
procedures to private practitioners was fraudulent.
Two important points should be made regarding fi-
nancing of EVR in France. The first is that the Huriet Act
protects patients from incurring any expense related to
clinical investigation. According to French law, the trial
initiator is responsible for all research-related expenses, ie,
the cost of the device or drug being tested and any addi-
tional examinations or procedures required by its use, as
well as for obtaining insurance to cover patient risk. The
Healthcare Financing Administration covers only expenses
corresponding to regular treatment expenses for the pa-
tient’s condition. This cost-sharing system between the
trial initiator and the Healthcare Financing Administration
has worked better for drug trials implicating large pharma-
ceutical firms than for medical device research, which often
involves firms with more limited resources. Financing re-
quirements in France that may have encouraged some
manufacturers to carry out clinical research in countries
with more favorable policies should be improved in the
future.
The second important point concerning financing of
EVR in France is that in practice public hospital endow-
ment funds have paid for AEPs more often than Research
Instigators. Public health practitioners have justified their
decision to devote public funds to AEPs on the basis that
clinical research is an important part of the public hospital
teaching function. However, analysis of accountancy re-
ports shows that such outlays are rarely reported as re-
search-related expenses. This finding suggests that there is a
tendency for some public officials to treat AEP insertion as
a routine rather than an experimental procedure. This
attitude is in agreement with the failure of practitioners to
perform EVR in an investigational setting.
The Huriet Act may have been perceived by French
practitioners as an unnecessary administrative impediment
to rapid application of a new medical technology. This
perception may have been reinforced in the minds of pri-
vate practitioners by access to endowment funds for financ-
ing AEPs in the public sector, which may have been per-
ceived as an unfair advantage. However, there is no reason
to think that the Huriet Act is impractical or incompatible
with current medical views and patient demands. Although
financing of clinical trials for medical device remains a
problem in France, the French system provides the same
regulatory framework for clinical investigation as the US
investigational device exemption system in the United
States.19 Devices must obtain CE approval on the basis of
in vitro bench testing and in vivo animal model research in
compliance with International Standards Organization
standards.7 Trial protocols must be authorized by an ethics
committee. Signed informed consent must be obtained
from patients. Furthermore, the Huriet Act has encoun-
tered no problems for therapeutic drug trials in France, and
the French system served as the basis for defining the April
4, 2001 European Community good clinical practices for
human therapeutic trials.
Several other findings of this study deserve comment.
There was a significant difference between the number of
AEPs used in public and private hospitals. Three possible
explanations can be given for this finding. The most likely
reason is that, as stated previously, French regulations
preventing reimbursement of EVR to private practitioners
favor public centers where CE-approved devices can be
financed through the facility’s annual endowment. In this
regard, it should be emphasized that patients are not de-
prived of treatment because French university public hos-
pitals are considered as reference centers open to all. The
second possible explanation is that some smaller private
hospitals were overlooked in this study despite every at-
tempt to avoid omitting any EVR because centers treating
fewer than 15 AAAs per year were excluded. The third
explanation is that publication of ANAES guidelines dis-
couraged private centers from performing EVR.
Another finding is the significantly higher re-interven-
tion rate in private institutions. This difference could have
been related to the lower number of procedures performed
by private practitioners (4.3 patients per center) as com-
pared with public practitioners (20.3 patients per center).
This could have created an experience gap, which placed
the private sector lower on the learning curve. This possi-
bility is supported by the fact that the public and private
patient populations were similar with regard to gravity of
disease and type of aortic aneurysm.
Nine institutions in this study implanted only one AEP
for AAA during the 2-year study period. A possible expla-
nation for this daunting finding is that some practitioners
used EVR to enhance their image. Like the experience-gap
problem mentioned in the previous paragraph, use of EVR
for self-promotion constitutes a sound argument for limit-
ing EVR trials to a few public and private centers. These
public and private centers could be chosen depending on
number of patients with treated AAAs, results of conven-
tional open repair, and expertise in endovascular tech-
niques.
The problems described herein demonstrate that pre-
vious attempts to organize development of new medical
technologies in France have so far failed. In the 1990s, the
CNAMTS unsuccessfully proposed the “single booking-
office” approach to medical research in which all parties
involved—government, scientific societies, manufacturers,
health financing administration, and health care agencies—
would select techniques for evaluation and define the mo-
dalities of study and financing. In 1997, the CNAMTS
(ENSM decree 1912-1997) decided to encourage clinical
studies within the framework of the Huriet Act in the
private sector and the French Society of Vascular Surgery
set up an independent AEP register. The law of July 8,
1998 mandated the mission of evaluating medical devices
to the AFSSAPS, but this agency was initially better suited
to device vigilance than clinical evaluation.
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The main question raised by this study is what can be
done to ensure first that the fundamental rules on human
experimentation and professional ethics are respected in
public and private practice in France and second that valu-
able trial data are no longer lost because of noncompliance
with legislative and clinical requirements for clinical re-
search. In July 2001, the AFSSAPS issued a statement7 that
basically confirmed the guidelines proposed by the ANAES
in 19996 and recommended use of AEPs only for high-risk
patients with aneurysms having a diameter greater than 50
mm or expanding at a rate greater than 1 cm per year.
However, this belated action has had no effect on the
situation. Hope for the future may lie in the upcoming
harmonization of French and European legislation. This
process could provide more flexibility in financing policy
defined by the Huriet Act and lead to stricter protection of
patient rights. In summary, this survey demonstrates that
EVR with AEP for AAA has not been properly used in
France and that clinical evaluation of AEPs has not been
carried out in accordance with recommendations of the
ANAES agency.6 Development of new technologies in-
volving medical devices continues to pose a major challenge
in France. In the future, a better cooperation between
different national authorities involved in the process and
between the European competent authorities shall improve
the evaluation of these new technologies.
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